Silexion Therapeutics Corp. (SLXN) intrinsic value & 10-year financials
Silexion Therapeutics Corp. (SLXN) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue reached to -$142.0K, with an average return on invested capital of 139.6%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.15
- Market cap
- $203.4K
- Revenue (FY2025)
- -$142.0K
- ROIC (10-yr avg)
- 139.6%
- Free cash flow (FY2025)
- -$10.8M
SLXN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | -$142.0K | -$11.9M | $8.96 | -$10.8M | 8191.5% | 294.1% |
| FY2024 | -$1.0K | -$16.5M | $26.36 | -$8.4M | 1257100.0% | 101.3% |
| FY2023 | -$153.0K | -$5.1M | $44.23 | -$4.5M | 3059.5% | 23.4% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Silexion Therapeutics Corp revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Silexion Therapeutics Corp has earned high returns on invested capital, averaging 42.5% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Silexion Therapeutics Corp capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Silexion Therapeutics Corp is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.